Clinical Medicine Articles
-
How can Nuvonis help to fight the SARS-CoV-2 pandemics?
At the end of the year 2019, a cluster of severe pneumonia of unknown cause was described in Wuhan (Eastern China) and a SARS-like acute respiratory distress syndrome (ARDS) was noted in these patients. Early in January 2020, sequencing revealed a novel coronavirus (now termed SARS-CoV-2) as the causal factor for the disease designated as COVID-19. The pandemic caused by the virus has unforeseen ...
By Nuvonis
-
Executive Summary Biofilm Testing of Irrisept Antimicrobial Wound Lavage in an In Vitro Model - Case Study
Objective An in vitro test was carried out to assess the ability of the Irrisept Antimicrobial Wound Lavage (Irrisept) device to disrupt and reduce clinically relevant biofilms. The testing approach used methods adapted from ASTM E2871-19, “Standard Test Method for Determining Disinfection Efficacy Against Biofilm Grown in the CDC Biofilm Reactor Using the Single Tube ...
-
The novel suspension quail cell line CCX.E10 is an ideal cell substrate for NDV virus and vector production
Newcastle disease is a highly infectious viral disease of the avian species. The causative agent is Newcastle disease virus (NDV), which belongs to the family of Paramyxoviridae. Many commercial vaccines, both live and inactivated, are available on the market and protect from NDV infection and disease. In addition, viral vectors based on Newcastle disease virus have been previously ...
By Nuvonis
-
What are Vero cells?
Vero cellsare a continuous adherent cell line that is frequently used in cell culture and plays an important role in worldwide vaccine and vector production (manufacturing). Unlike other mammalian cells, they do not secrete interferon alpha or beta when infected by viruses – this is one of the reasons that efficient replication of many viruses can be achieved in Vero cells, ...
By Nuvonis
-
hVIVO used Nuvonis’ GMP Vero cells to produce Novel SARS-CoV-2 virus for a human challenge model
One of the main benefits of using Nuvonis’ fully tested GMP Vero cells is the unparalleled speed towards clinical trials. A case example from one of our customers, hVIVO: First contact with Nuvonis in July 2020, due diligence, contracting, provision of GMP Vero cells and protocols, as well as full documentation Production of GMP material in November 2020 ...
By Nuvonis
-
Rho kinase inhibition in Amyotrophic Lateral Sclerosis - Case Study
REAL is a phase 2a open-label study to assess preliminary safety, tolerability, and effect on clinical outcomes as well as neurodegeneration biomarkers of BRAVYL in patients with ALS. The study will enroll approximately 20 patients, all of whom will be treated with BRAVYL for 24 weeks. ...
-
Medical Battery Pack - Most Common Applications
Why Do You Need One? A medical battery pack is an essential part of any medical device. It provides power to the device when no other power source is available. This kinf of battery pack can be used on a number of devices, including portable defibrillators, heart monitors and other life-saving devices. There are many different types of medical battery pack manufacturing on the market today. ...
-
Protein N-Glycosylation Analysis Strategy and Procedures
The glycan chain is located in the outermost layer of the cell and is the first molecule encountered and recognized by other cells, antibodies, invading viruses and bacteria. N-glycans regulate a wide range of cellular functions, including cell-cell and cell-matrix adhesion, cell proliferation, cell survival and immune system response, by affecting protein folding, recognition, clearance, ...
-
Project - Sublingual insulin+ (fixed dose combination product of insulin and exenatide/liraglutide)
The global human insulin market is projected to surpass USD 40 Billion USD. Our sublingual “insulin+” product will be positioned in a particular segment of this market : it will be prescribed for type II diabetes patients, who do not respond sufficiently to GLP-1 analogues alone. Such a fixed dose combination is already on the market under the brand name Xultophy, which is a ...
By BioLingus AG
-
Project - Sublingual Interferon-alfa (BL SLIT II)
We plan to develop sublingual interferon-alfa for the prevention of viral infections, such as influenza and coronaviruses (such as COVID-19). The rise in prevalence of viral respiratory infections in humans and increase in health care expenditure are projected to boost the growth of the global respiratory antiviral treatment market. Respiratory syncytial virus, influenza virus, parainfluenza ...
By BioLingus AG
-
Project - Sublingual Exenatide
Liraglutide and exenatide are both belonging to the class of diabetes products called GLP-1 analogues. The GLP-1 analogues have established themselves in the past years as one of the superior drug classes for treatment of diabetes type II in terms of blood glucose lowering and weight loss. Because of the latter, they are being used more and more also in the treatment of obesity. Until now, both ...
By BioLingus AG
-
Difference Between Exogenous and Endogenous Protein Crosslinking
What is protein cross-linking? Protein crosslinking usually refers to the joining of two amino acids in a protein by a covalent bond other than a peptide bond. Protein crosslinking includes both intermolecular and intramolecular crosslinking, which are distinguished by whether the amino acids attached at the ends of the crosslink are from the same protein. The connected parts can be divided into ...
-
Project - Sublingual Dual Incretin Inhibitor (GLP-1/GIP)
Biolingus explores the development of a sublingual dual incretin inhibitor. BioLingus will position these products in the “epidemic” markets of obesity and type II diabetes : More than 400 MM people suffer from diabetes today. The global type 2 diabetes market is expected to grow to $58.7 billion by 2025, with an annual growth rate of 6.5%, according to research and consulting ...
By BioLingus AG
-
Project - Sublingual IL2 (BL SLIT I)
The aim of this project is to develop low dose IL-2 for treatment of early onset juvenile Type I diabetes. Low dose injectable IL-2 in animal models has been shown to restore the balance between regulatory and effector T cells and, in this way, can help to reverse autoimmunity and the development of type I diabetes. Looking ahead, we anticipate that having a suitable oral formulation of IL-2 to ...
By BioLingus AG
-
Project - Sublingual Semaglutide
Semaglutide is currently the only GLP-1 product available as an oral product. Biolingus aims at developing a sublingual version of this product. This should have a substantially lower COGS and hence competitive with the oral ...
By BioLingus AG
-
Targeted Region Sequencing in Human Disease Studies and Clinical Care
Introduction to target region sequencing Since the introduction of Sanger sequencing in 1977, genetic sequencing has been greatly improved with costs simultaneously falling. With the ability to rapidly produce large volumes of sequencing data, next-generation sequencing (NGS) enables researchers to obtain whole genome or targeted regions of samples. Targeted region sequencing is preferred by ...
By CD Genomics
-
PEG Linkers for Antibody Drug Conjugates
Antibody-drug conjugate (ADC) is one of the fastest growing fields in tumor therapy, which consists of monoclonal antibody (Antibody), linker (Linker) and active drug (Payload). So far, there are only 15 drugs on the market in the world. However, with the development of some perfect antibody modification techniques, advanced site-specific coupling techniques and powerful small-molecule toxins, ...
-
Vaccine Freezers for Vaccine Storage and Handling
Vaccine Freezers are required for the safe storage of vaccines that must be kept at extremely low temperatures. Without sufficient storage, a vaccine is likely to form deviations, drastically impacting the vaccines efficiency. At Froilabo we work to support the medical and pharmaceutical industry with the equipment they require to ensure safe storage solutions. Vaccine storage has been in high ...
-
Indication selection for anti-PDx combination therapy In collaboration with big pharma - Case Study
The Challenge: One of the most common challenges in immuno-oncology is identifying the indications and patient populations that would benefit from a specific therapy, especially on top of Standard of Care (SOC) treatments. Our platform tackled this challenge of indication prioritization and patient stratification for a combination of a specific target (A) with an anti-PDX drug that one of our ...
By CytoReason
-
Identifying a combination benefit of a Ph-3 drug with an SOC drug In collaboration with big pharma - Case Study
The Challenge: To understand the molecular effect of a ph-3 drug (Drug A) which showed moderate outcomes and to recommend next steps to increase response ...
By CytoReason
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you